LL-OVA Syngeneic Model Service for Lung Cancer

The LL-OVA syngeneic model of lung cancer equips the historic Lewis lung carcinoma—rapidly growing, weakly immunogenic, spontaneously metastatic—with a defined ovalbumin antigen for tracking tumor-specific T-cell responses in immunocompetent C57BL/6 hosts. Alfa Cytology delivers the complete LL-OVA workflow—authenticated cell banking, intravenous pulmonary or subcutaneous implantation, OT-I/OT-II-compatible designs, radiation and vaccine intervention schedules, and antigen-specific endpoint analysis—giving sponsors decision-ready preclinical datasets shaped to their program, strictly within a preclinical scope.

Overview of LL-OVA Syngeneic Model for Lung Cancer

LL-OVA descends from one of the oldest transplantable tumors in oncology. In 1951, Margaret Lewis described a spontaneous carcinoma arising in the lung of a C57BL/6 mouse; serial passage yielded the Lewis lung carcinoma (LLC, distributed as LL/2, ATCC CRL-1642), and for decades it has served as the default immunocompetent lung cancer model—doubling every 8–12 hours in culture, highly tumorigenic, spontaneously metastatic to lung from flank implants, and—as the antigen-therapy literature emphasizes—only weakly immunogenic. Engineering it with chicken ovalbumin cDNA produced LL-OVA (LLC-OVA), whose processed epitopes—SIINFEKL (OVA257–264) on H-2K^b and OVA323–339 on I-A^b—make every experiment with OT-I and OT-II transgenic T cells quantitatively readable through tetramers, the 25-D1.16 antibody and cytokine readouts.

Fig 1. Combination therapy increases numbers of InsB12–20⁺ Foxp3⁺ CD4⁺ T cells in islet grafts. (Devlies, Wout, et al., 2020)

The model’s flagship format is pulmonary dissemination: half a million cells injected intravenously colonize the lung within about three weeks as multiple surface nodules, and because the tumors burden ventilation, whole-body plethysmography—compliance, dynamic compliance, airway resistance—becomes a live efficacy readout, a feature exploited in gemcitabine benchmarking where metronomic oral gemcitabine matched maximum-tolerated dosing. Subcutaneous implants grow brisk primaries with spontaneous lung metastasis, and here the line has contributed a classic radiation-immunotherapy result: a single local dose of 18–20 Gy combined with adoptively transferred OT-II-derived Th1 cells produced cooperative antitumor effects. In vaccine biology, LL-OVA occupies a special niche: in gp96-Ig-OVA systems, an established LL-OVA flank tumor measurably suppresses antigen-specific OT-I expansion—evidence that progressing lung tumors actively restrain T-cell immunity—while OVA gene-modified dendritic-cell vaccines shrink LL-OVA tumors and prolong survival. Caveats mirror those of other OVA lines: a 1951-era parental heritage with subline variation, a genuinely weak endogenous immunogenicity that limits single-agent T-cell control, expression drift under immune pressure, and the model-antigen translation gap.

Cell Line Information: LL-OVA

Key characteristics of LL-OVA and its parental heritage are summarized below.

Our Services

With in vivo oncology specialists guiding each stage and pathology, pulmonary-function testing, bioluminescence imaging and immune-profiling capabilities in-house, Alfa Cytology molds every LL-OVA engagement around the sponsor’s question—selecting the intravenous pulmonary or flank format, coordinating OT-I/OT-II logistics, and pairing interventions with ventilation, metastasis and tetramer-based readouts for clean, decision-grade preclinical data.

Workflow of LL-OVA Syngeneic Model Construction

Construction of the LL-OVA syngeneic model is an inoculation workflow whose quality rests on verified antigen expression, vigorous C57BL/6 recipients, route-matched technique and disciplined monitoring. A standard engagement proceeds as follows:

1. Source and qualify cells: LL-OVA stocks are cleared by mycoplasma PCR and identity-verified, with OVA expression confirmed by Western blot and SIINFEKL–H-2K^b staining (25-D1.16); selection is maintained during expansion to guard against antigen loss, and luciferase labeling is titrated in vitro where imaging is required.
2. Prepare recipients: C57BL/6 mice (typically 6–8 weeks old; OT-I/OT-II transgenic or congenically marked hosts where antigen-specific designs call for them) complete acclimation and health screening.
3. Prepare the inoculum: log-phase cells are harvested, washed, counted and resuspended in PBS (commonly 5 × 10⁵ cells in 150 µL for the pulmonary format; 5 × 10⁵–1 × 10⁶ cells in 100 µL for flank implants).
4. Inoculate: for pulmonary dissemination, cells are injected into the tail vein; for the flank format, cells are injected subcutaneously with consistent anatomical positioning; intratracheal or orthotopic lung implantation variants are available where organ context is required.
5. Assign groups: flank-format animals are randomized when tumors reach palpability, balanced by tumor volume and body weight; pulmonary-format cohorts are randomized at inoculation by body weight.
6. Dose and follow: test articles (checkpoint agents, vaccines, radiation fractions, metronomic regimens) are administered on schedule; flank tumors are measured with calipers two to three times weekly (volume typically 0.52 × length × width²); pulmonary cohorts are followed by body weight, respiratory scoring and periodic whole-body plethysmography, with survival recorded.
7. Terminate and analyze: flank tumors are resected and weighed; lungs are weighed and nodules counted with H&E confirmation; tumor and splenic T cells are analyzed by flow cytometry with H-2K^b–SIINFEKL tetramers and activation/exhaustion panels; sections are stained with 25-D1.16 and CD3; tissues enter histopathology and molecular analysis.

Fig 2. LL-OVA Syngeneic Model construction workflow.

Case Study-LL-OVA Syngeneic Model Development

Alfa Cytology maintains an active preclinical case-study file on the LL-OVA platform: establishment-phase verification of antigen expression and growth kinetics, in vivo pulmonary and flank tracking by plethysmography, caliper or bioluminescence, vaccine- and radiation-based intervention studies with OT-I/OT-II readouts, and systematic lung metastasis quantification with matched antigen-specific immune profiling. Representative growth curves, ventilation datasets and endpoint summaries can be shared upon request and will be updated as new programs conclude.

Why Choose Alfa Cytology?

LL-OVA’s double identity—historic, weakly immunogenic lung tumor plus defined antigen—demands both classical execution and antigen-specific finesse, which is where Alfa Cytology invests:

• Dual-format execution spanning intravenous pulmonary colonization and flank implantation, with orthotopic variants.
• Authenticated LL-OVA banks with 25-D1.16-verified antigen expression and enforced selection maintenance.
• Pulmonary-function capability (whole-body plethysmography) as a live, humane efficacy readout.
• Radiation-immunotherapy experience reflecting the documented 18–20 Gy plus OT-II Th1 precedent.
• OT-I/OT-II logistics and tetramer-based endpoint profiling in-house.
• Fast-kinetics planning around the 8–12-hour doubling schedule.
• One accountable project contact with milestone-by-milestone visibility.
• A strictly preclinical scope—every study is planned, executed and reported as non-clinical research.

Contact Us

Interested in the LL-OVA syngeneic lung cancer model for your next preclinical program? Reach out to us with your agent, timeline and endpoint wish-list, and the Alfa Cytology team will respond with a customized plan covering model setup, dosing strategy and analysis workflow—contact us today and move your program forward with confidence.

For research use only. Not intended for any clinical use.